A novel inhibitor of human cytomegalovirus acts through a specific antiviral mechanism that involves the helicase-primase complex. (PubMed, Antimicrob Agents Chemother) - Jul 14, 2026 - "The terminase inhibitor (letermovir) and viral UL97 kinase inhibitor (maribavir) have improved the CMV armamentarium; however, both select for resistance, and have limited therapeutic indications...While its maximal time of HCMV inhibition overlaps with ganciclovir (GCV), it remains active against GCV-resistant strains, suggesting a distinct mechanism involving the CMV replisome...Sequence alignment revealed some similarity between GPCMV and HCMV UL70 486-487. In summary, we identified an inhibitor of HCMV replication that acts through a novel mechanism involving the H/P complex, opening new avenues in the development of HCMV-specific drugs."
Journal • Cytomegalovirus Infection • Transplantation
|
|
Alyza Skaist; Arun Kapoor; Ayan K Ghosh; Michael Forman; Ravit Arav-Boger; Sarah Wheelan
|